Encouraging Interim Trial Results for Hep C Non-Responders
Share
Follow Us
The Editors at Hepatitis Central
October 25, 2011
After just three months of a Phase 2b study, Setrobuvir with pegylated interferon and ribavirin led to undetectable viral levels in over three quarters of previous Hepatitis C treatment non-responders.
Anadys achieves positive interim results in ongoing phase 2b hepatitis C study
October 13, 2011
by Olivia D’Orazio
Anadys Pharmaceuticals (NASDAQ:ANDS) announced Thursday positive interim results in its ongoing phase 2b study of setrobuvir, in combination with pegylated interferon and ribavirin (P/R), in patients with the hepatitis C virus.
The study dosed 283 patients suffering from hepatitis C, who were either treatment naive, or experienced either a relapse or no response to previous P/R treatments.
Continue reading this entire article:
http://www.proactiveinvestors.com/companies/news/19618/anadys-achieves-positive-interim-results-in-ongoing-phase-2b-hepatitis-c-study-19618.html
